Insulin and incretin receptor agonists reciprocally alter their blood-brain barrier permeability

Dysregulated brain insulin signaling is a frequent feature of Alzheimer's disease (AD), contributing to cognitive impairment. While antidiabetic incretin receptor agonists (IRAs) show promise in restoring brain insulin signaling and reversing neurodegenerative characteristics in animal models, the mechanisms driving these effects remain poorly understood. A key knowledge gap exists regarding how IRAs interact with the blood-brain barrier (BBB), a critical interface controlling brain entry of therapeutics and endogenous peptides.

The study investigated the interactions between insulin and incretin receptor agonists (IRAs) at the blood-brain barrier (BBB). While specific experimental details such as the exact model (e.g., in vitro BBB model or preclinical-animal species), sample size (n), dose, route, or duration are not provided in the abstract snippet, the research aimed to determine if these peptide classes reciprocally influence each other's permeability across the BBB. The primary focus was on understanding how the presence of one agonist affects the brain entry or efflux kinetics of the other.